Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment

Cancer Biology and Therapy

Volumn 17, Issue 6, 2016, Pages 698-707

  Wang, Tao ^a   Narayanaswamy, Radhika ^a   Ren, Huilan ^a   Torchilin, Vladimir P ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Breast cancer; cancer stem like cell; combination therapy; mammosphere; salinomycin

Indexed keywords

CD24 ANTIGEN; DOXORUBICIN; HERMES ANTIGEN; PACLITAXEL; SALINOMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; STEM CELL SELF-RENEWAL; BREAST NEOPLASMS; FEMALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84977653541     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1190488     Document Type: Article

References (45)

1. S.Bapst, ed. Cancer Stem Cells. New Jersey: A John Wiley & Sons, Inc.; 2009
2. E.A.McCulloch, J.E.Till. Perspectives on the properties of stem cells. Nat Med 2005; 11:1026-8; PMID:16211027; http://dx.doi.org/10.1038/nm1005-1026
3. D.E.Bergsagel, F.A.Valeriote. Growth characteristics of a mouse plasma cell tumor. Cancer Res 1968; 28:2187-96; PMID:5723963
4. T.Lapidot, C.Sirard, J.Vormoor, B.Murdoch, T.Hoang, J.Caceres-Cortes, M.Minden, B.Paterson, M.A.Caligiuri, J.E.Dick. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8; PMID:7509044; http://dx.doi.org/10.1038/367645a0
5. M.Al-Hajj, M.S.Wicha, A.Benito-Hernandez, S.J.Morrison, M.F.Clarke. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas.0530291100
6. S.K.Singh, C.Hawkins, I.D.Clarke, J.A.Squire, J.Bayani, T.Hide, R.M.Henkelman, M.D.Cusimano, P.B.Dirks. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401; PMID:15549107; http://dx.doi.org/10.1038/nature03128
7. S.K.Singh, I.D.Clarke, M.Terasaki, V.E.Bonn, C.Hawkins, J.Squire, P.B.Dirks. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8; PMID:14522905
8. Yu, John S. (Ed.) Cancer Stem Cells, Methods and Protocols, Methods in Molecular Biology.Volume 568 2009. ISBN: 978-1-58829-938-3 (Print) 978-1-59745-280-9 (Online). Humana Press. New York City. www.springer.com/humana
9. M.Al-Hajj, M.F.Clarke. Self-renewal and solid tumor stem cells. Oncogene 2004; 23:7274-82; PMID:15378087; http://dx.doi.org/10.1038/sj.onc.1207947
10. C.Hirschmann-Jax, A.E.Foster, G.G.Wulf, J.G.Nuchtern, T.W.Jax, U.Gobel, M.A.Goodell, M.K.Brenner. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101:14228-33; PMID:15381773; http://dx.doi.org/10.1073/pnas.0400067101
11. S.P.McDermott, M.S.Wicha. Targeting breast cancer stem cells. Mol Oncol 2010; 4:404-19; PMID:20599450; http://dx.doi.org/10.1016/j.molonc.2010.06.005
12. C.J.Creighton, X.Li, M.Landis, J.M.Dixon, V.M.Neumeister, A.Sjolund, D.L.Rimm, H.Wong, A.Rodriguez, J.I.Herschkowitz, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009; 106:13820-5; PMID:19666588; http://dx.doi.org/10.1073/pnas.0905718106
13. S.Bao, Q.Wu, R.E.McLendon, Y.Hao, Q.Shi, A.B.Hjelmeland, M.W.Dewhirst, D.D.Bigner, J.N.Rich. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236
14. X.Li, M.T.Lewis, J.Huang, C.Gutierrez, C.K.Osborne, M.F.Wu, S.G.Hilsenbeck, A.Pavlick, X.Zhang, G.C.Chamness, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672-9; PMID:18445819; http://dx.doi.org/10.1093/jnci/djn123
15. F.Yu, H.Yao, P.Zhu, X.Zhang, Q.Pan, C.Gong, Y.Huang, X.Hu, F.Su, J.Lieberman, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109-23; PMID:18083101; http://dx.doi.org/10.1016/j.cell.2007.10.054
16. M.R.Bardsley, V.J.Horvath, D.T.Asuzu, A.Lorincz, D.Redelman, Y.Hayashi, L.N.Popko, D.L.Young, G.A.Lomberk, R.A.Urrutia, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139:942-52; PMID:20621681; http://dx.doi.org/10.1053/j.gastro.2010.05.083
17. P.B.Gupta, T.T.Onder, G.Jiang, K.Tao, C.Kuperwasser, R.A.Weinberg, E.S.Lander. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59; PMID:19682730; http://dx.doi.org/10.1016/j.cell.2009.06.034
18. C.Naujokat, R.Steinhart. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012; 2012:950658; PMID:23251084; http://dx.doi.org/10.1155/2012/950658
19. F.Kopp, A.Hermawan, P.S.Oak, A.Herrmann, E.Wagner, A.Roidl. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer 2014; 13:16; PMID:24468090; http://dx.doi.org/10.1186/1476-4598-13-16
20. Q.L.Tang, Z.Q.Zhao, J.C.Li, Y.Liang, J.Q.Yin, C.Y.Zou, X.B.Xie, Y.X.Zeng, J.N.Shen, T.Kang, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 2011; 311:113-21; PMID:21835542; http://dx.doi.org/10.1016/j.canlet.2011.07.016
21. R.Riccioni, M.L.Dupuis, M.Bernabei, E.Petrucci, L.Pasquini, G.Mariani, M.Cianfriglia, U.Testa. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45:86-92; PMID:20444629; http://dx.doi.org/10.1016/j.bcmd.2010.03.008
22. M.S.Chen, W.A.Woodward, F.Behbod, S.Peddibhotla, M.P.Alfaro, T.A.Buchholz, J.M.Rosen. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007; 120:468-77; PMID:17227796; http://dx.doi.org/10.1242/jcs.03348
23. W.A.Woodward, M.S.Chen, F.Behbod, M.P.Alfaro, T.A.Buchholz, J.M.Rosen. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007; 104:618-23; PMID:17202265; http://dx.doi.org/10.1073/pnas.0606599104
24. Y.Teng, X.Wang, Y.Wang, D.Ma. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010; 392:373-9; PMID:20074550; http://dx.doi.org/10.1016/j.bbrc.2010.01.028
25. M.Mitani, T.Yamanishi, Y.Miyazaki, N.Otake. Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother 1976; 9:655-60; PMID:131509; http://dx.doi.org/10.1128/AAC.9.4.655
26. S.Patel, P.Rameshwar. Cancer Stem cells. Protocol Exchange; http://dx.doi.org/1038/protex.2013.023
27. G.Dontu, W.M.Abdallah, J.M.Foley, K.W.Jackson, M.F.Clarke, M.J.Kawamura, M.S.Wicha. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17:1253-70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803
28. P.Van PhamPhuc, B.Thanh VuBinh, N.L.Chinh PhanNhan Lu, et al., eds. Biomedical Tissue Culture,: InTech; 2012; http://dx.doi.org/10.5772/3071
29. T.Kondo. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007; 3:245-50; PMID:17917153
30. M.Simian, Y.Hirai, M.Navre, Z.Werb, A.Lochter, M.J.Bissell. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 2001; 128:3117-31; PMID:11688561
31. T.Gudjonsson, R.Villadsen, H.L.Nielsen, L.Ronnov-Jessen, M.J.Bissell, O.W.Petersen. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 2002; 16:693-706; PMID:11914275; http://dx.doi.org/10.1101/gad.952602
32. O.W.Petersen, L.Ronnov-Jessen, A.R.Howlett, M.J.Bissell. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A 1992; 89:9064-8; PMID:1384042; http://dx.doi.org/10.1073/pnas.89.19.9064
33. S.A.Mani, W.Guo, M.J.Liao, E.N.Eaton, A.Ayyanan, A.Y.Zhou, M.Brooks, F.Reinhard, C.C.Zhang, M.Shipitsin, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027
34. T.Brabletz, A.Jung, S.Spaderna, F.Hlubek, T.Kirchner. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5:744-9; PMID:16148886; http://dx.doi.org/10.1038/nrc1694
35. Y.Zhang, H.Zhang, X.Wang, J.Wang, X.Zhang, Q.Zhang. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012; 33:679-91; PMID:22019123; http://dx.doi.org/10.1016/j.biomaterials.2011.09.072
36. J.H.Kim, M.Chae, W.K.Kim, Y.J.Kim, H.S.Kang, H.S.Kim, S.Yoon. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol 2011; 162:773-84; PMID:20973777; http://dx.doi.org/10.1111/j.1476-5381.2010.01089.x
37. V.Rausch, L.Liu, G.Kallifatidis, B.Baumann, J.Mattern, J.Gladkich, T.Wirth, P.Schemmer, M.W.Büchler, M.Zöller, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010; 70:5004-13; PMID:20530687; http://dx.doi.org/10.1158/0008-5472.CAN-10-0066
38. G.Honeth, P.O.Bendahl, M.Ringner, L.H.Saal, S.K.Gruvberger-Saal, K.Lövgren, D.Grabau, M.Fernö, A.Borg, C.Hegardt. The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10:R53; PMID:18559090; http://dx.doi.org/10.1186/bcr2108
39. T.O.Nielsen, F.D.Hsu, K.Jensen, M.Cheang, G.Karaca, Z.Hu, T.Hernandez-Boussard, C.Livasy, D.Cowan, L.Dressler, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-74; PMID:15328174; http://dx.doi.org/10.1158/1078-0432.CCR-04-0220
40. D.L.Holliday, V.Speirs. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011; 13:215; PMID:21884641; http://dx.doi.org/10.1186/bcr2889
41. S.Ricardo, A.F.Vieira, R.Gerhard, D.Leitão, R.Pinto, J.F.Cameselle-Teijeiro, F.Milanezi, F.Schmitt, J.Paredes. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64:937-46; PMID:21680574; http://dx.doi.org/10.1136/jcp.2011.090456
42. M.Shipitsin, L.L.Campbell, P.Argani, S.Weremowicz, N.Bloushtain-Qimron, J.Yao, T.Nikolskaya, T.Serebryiskaya, R.Beroukhim, M.Hu, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259-73; PMID:17349583; http://dx.doi.org/10.1016/j.ccr.2007.01.013
43. S.Y.Park, H.E.Lee, H.Li, M.Shipitsin, R.Gelman, K.Polyak. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16:876-87; PMID:20103682; http://dx.doi.org/10.1158/1078-0432.CCR-09-1532
44. C.M.Fillmore, C.Kuperwasser. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:R25; PMID:18366788; http://dx.doi.org/10.1186/bcr1982
45. C.Sheridan, H.Kishimoto, R.K.Fuchs, S.Mehrotra, P.Bhat-Nakshatri, C.H.Turner, R.GouletJr, S.Badve, H.Nakshatri. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8:R59; PMID:17062128; http://dx.doi.org/10.1186/bcr1610